Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT04628780. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Study identification
- NCT ID
- NCT04628780
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 37 participants
Conditions and interventions
Conditions
Interventions
- PF-07209960 Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 15, 2020
- Primary completion
- May 2, 2023
- Completion
- May 25, 2023
- Last update posted
- Jul 28, 2024
2020 – 2023
United States locations
- U.S. sites
- 13
- U.S. states
- 3
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Investigational Drug Service (IDS) | Duarte | California | 91010 | — |
| City of Hope | Duarte | California | 91010 | — |
| Ronald Reagan UCLA Medical Center | Los Angeles | California | 90095 | — |
| UCLA Hematology/Oncology | Los Angeles | California | 90095 | — |
| Santa Monica UCLA Medical Center & Orthopaedic Hospital | Santa Monica | California | 90404 | — |
| UCLA Hematology Oncology - Santa Monica | Santa Monica | California | 90404 | — |
| Tennessee Oncology PLLC | Nashville | Tennessee | 37203 | — |
| The Sarah Cannon Research Institute/Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| TriStar Centennial Medical Center | Nashville | Tennessee | 37203 | — |
| The University of Texas MD Anderson Cancer Center- Investigational Pharmacy | Houston | Texas | 77030 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Christus Santa Rosa Hospital | San Antonio | Texas | 78229 | — |
| NEXT Oncology | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04628780, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 28, 2024 · Synced May 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04628780 live on ClinicalTrials.gov.